Risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy in the Northwest Region of Cameroon

[1] Osakunor D(2015)Hepatic enzyme alterations in HIV patients on antiretroviral therapy: A Case-Control Study in a Hospital Setting in Ghana PLOS ONE 10 e0134449-23

[2] Obirikorang C(2015)Anti-retroviral drug hepatotoxicity and risk factors in HIV patients with or without hepatitis B and C: a review J Infect Dis Ther 3 258-12

[3] Fianu V(2011)Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting Afr Health Sci. 11 16-057

[4] Asare I(2010)Liver disease in the HIV-infected individual Clin Gastroenterol Hepatol 8 1002-1382

[5] Dakorah M(2010)Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART Programme in South Africa PLoS ONE 5 e9183-26

[6] Wambani JR(2010)Evaluation of hepatotoxicity and nephrotoxicity in HIV patients on highly active antiretroviral therapy J AIDS HIV Res 2 048-54

[7] Ogola PE(2014)Prevalence and risk factors for hepatotoxicity among patients with HIV/AIDS on highly active antiretroviral therapy in North-Western Nigeria Sub-Saharan Afr J Med 1 175-9

[8] Arika WM(2000)Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection JAMA 283 74-236

[9] Rachuonyo HO(2007)The Prevalence and Risk Factors for Abnormal Liver Enzymes in HIV-Positive Patients without Hepatitis B or C Co-infections Dig. Dis. Sci. 53 1375-227

[10] Kemboi NG(2012)Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania PLoS ONE 7 e40180-1093

[1] Osakunor D(2015)Hepatic enzyme alterations in HIV patients on antiretroviral therapy: A Case-Control Study in a Hospital Setting in Ghana PLOS ONE 10 e0134449-23

[2] Obirikorang C(2015)Anti-retroviral drug hepatotoxicity and risk factors in HIV patients with or without hepatitis B and C: a review J Infect Dis Ther 3 258-12

[3] Fianu V(2011)Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting Afr Health Sci. 11 16-057

[4] Asare I(2010)Liver disease in the HIV-infected individual Clin Gastroenterol Hepatol 8 1002-1382

[5] Dakorah M(2010)Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART Programme in South Africa PLoS ONE 5 e9183-26

[6] Wambani JR(2010)Evaluation of hepatotoxicity and nephrotoxicity in HIV patients on highly active antiretroviral therapy J AIDS HIV Res 2 048-54

[7] Ogola PE(2014)Prevalence and risk factors for hepatotoxicity among patients with HIV/AIDS on highly active antiretroviral therapy in North-Western Nigeria Sub-Saharan Afr J Med 1 175-9

[8] Arika WM(2000)Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection JAMA 283 74-236

[9] Rachuonyo HO(2007)The Prevalence and Risk Factors for Abnormal Liver Enzymes in HIV-Positive Patients without Hepatitis B or C Co-infections Dig. Dis. Sci. 53 1375-227

[10] Kemboi NG(2012)Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania PLoS ONE 7 e40180-1093